Tenderwize
Zurück zur Suche

Open-house rebate agreement for tiotropium bromide inhalation solution

AOK Rheinland-Pfalz/Saarland - Die Gesundheitskasse·Eisenberg, Germany·Deadline Nov 30, 2027 · 462 days left·Open·Supplies
Originaltitel der Bekanntmachung

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge zum Wirkstoff Tiotropiumbromid, Darreichungsform Inhalationslösung, ATC R03BB04

52/100

Opportunity Score

Needs reviewMedium complexity
SuppliesOpen
Warum diese Bewertung?

Chance

52 / 100

Komplexität

58 / 100

Risikofaktoren

Submission is only valid if the buyer receives the signed originals or the qualified-electronic-signature version by th...

Participation is limited to pharmaceutical companies and to medicines that are authorised and marketable in Germany.

Tiefe Portfolioanalyse

Tiefe Analyse der Unternehmenspassung

Verwendet:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Überblick

Moderate opportunity

Wichtige Fakten

  • Supplies contract
  • 1 lot
  • Duration until Jan 2028
  • Non-exclusive open-house rebate agreements for pharmaceutical products containing tiotropium bromide, inhalation solution, ATC R03BB04.
  • Contract term up to 24 months, with earliest start on 2026-02-01 and automatic end no later than 2028-01-31.
Vollständige Zusammenfassung anzeigen

This is a German open-house supply notice for non-exclusive pharmaceutical rebate agreements for tiotropium bromide inhalation solution (ATC R03BB04) with AOK Rheinland-Pfalz/Saarland. The contract window runs from 2026-02-01 to 2028-01-31, with monthly entry possible during the period. No contract value is stated. Submission is by signed paper originals or by email with qualified electronic signature; electronic submission is otherwise not allowed. The notice explicitly excludes pediatric medicines on the BfArM list and limits participation to pharmaceutical companies.

Risiken

Submission is only valid if the buyer receives the signed originals or the qualified-electronic-signature version by th...

Participation is limited to pharmaceutical companies and to medicines that are authorised and marketable in Germany.

Analyse kann unvollständig sein

Nur ein Teil der Vergabeunterlagen wurde analysiert. Weitere Anforderungen, Zertifikate oder Einreichungsdokumente können in den übrigen Unterlagen enthalten sein.

Wichtige Anforderungen

Technical

  • Medicines must be approved and marketable in Germany.
  • If the medicine is already listed in Lauer-Taxe as marketable, that is treated as proof.

Eligibility

  • Only pharmaceutical companies are eligible to become contract partners.

Auftraggeber

Lose (1)

LOT-0001

Open-house rebate agreement for tiotropium bromide inhalation solution

Single lot open-house model for non-exclusive rebate agreements covering medicines with active substance tiotropium bromide, dosage form inhalation solution, ATC R03BB04. The buyer states that all interested pharmaceutical companies may join on equal terms, without selection or individual negotiation. Pediatric medicines listed by BfArM under § 35 Abs. 5a SGB V are excluded. Contract duration is up to 24 months, starting no earlier than 2026-02-01, with monthly entry possible during the term. Source: structured data and XML notice.

SuppliesEU fundedElectronic submission

Ort

Eisenberg, Germany

Dauer

Jan 2026 - Jan 2028

Kategorie

Pharmaceutical products

Frist

Deadline Nov 30, 2027

Vergabedetails

Veröffentlichungsdatum
09 Dec 2025
Sprachen
German

Referenzmetadaten

Rechtsgrundlage
32014L0024

Referenz-IDs

Ausschreibungs-ID
818511-2025

Dokumente (1)

Ähnliche Ausschreibungen